Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Isidoro González-Alvaro

Showing results (1-10 of 37) with videos related to

Pageof 4
Sort By:
Arthritis Research & Therapy|November 28, 2008
Trends towards an improved disease state in rheumatoid arthritis over time: influence of new therapies and changes in management approach: analysis of the EMECAR cohortIsidoro González-Alvaro, Miguel Angel Descalzo, Loreto Carmona, et al.
Reumatologia Clinica|July 29, 2011
Pattern of use and safety of non-steroidal anti-inflammatory drugs in rheumatoid arthritis patients. A prospective analysis from clinical practiceIván Ferraz-Amaro, Sergio Machín, Loreto Carmona, et al.
The Journal of Rheumatology|January 6, 2004
Value of Disease Activity Score 28 (DAS28) and DAS28-3 compared to American College of Rheumatology-defined remission in rheumatoid arthritisAlejandro Balsa, Loreto Carmona, Isidoro González-Alvaro, et al.
Medicina Clinica|June 7, 2002
[Variations in the drug treatment of rheumatoid arthritis in Spain]Isidoro González-Alvaro, César Hernández-García, Virginia Villaverde García, et al.
Seminars in Arthritis and Rheumatism|November 6, 2007
Cancer in rheumatoid arthritis: occurrence, mortality, and associated factors in a South European populationLydia Abásolo, Enrique Júdez, Miguel Angel Descalzo, et al.
Trials|September 10, 2020
Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trialRosario Garcia-Vicuña, Francisco Abad-Santos, Isidoro González-Alvaro, et al.
Diagnostics (Basel, Switzerland)|July 27, 2022
Anti-Citrullinated Protein Antibody Titers Are Independently Modulated by Both Disease Activity and Conventional or Biologic Anti-Rheumatic DrugsMiren Uriarte Ecenarro, Daniel Useros, Aranzazu Alfranca, et al.
The Journal of Rheumatology|May 18, 2010
Estimated cutoff points for the 28-joint disease activity score based on C-reactive protein in a longitudinal register of early arthritisIsabel Castrejón, Ana M Ortiz, Esther Toledano, et al.
Journal of Clinical Densitometry : the Official Journal of the International Society for Clinical Densitometry|June 19, 2007
Reproducibility of metacarpophalangeal bone mass measurements obtained by dual-energy X-ray absorptiometry in healthy volunteers and patients with early arthritisSantos Castañeda, Isidoro González-Alvaro, Francisco Rodríguez-Salvanés, et al.
Arthritis Research & Therapy|March 25, 2010
A rational use of glucocorticoids in patients with early arthritis has a minimal impact on bone massMonica Ibañez, Ana M Ortiz, Isabel Castrejón, et al.
Pageof 4

Showing results (1-10 of 37) with videos related to

Sort By:
Pageof 4
Arthritis Research & Therapy|November 28, 2008
Trends towards an improved disease state in rheumatoid arthritis over time: influence of new therapies and changes in management approach: analysis of the EMECAR cohortIsidoro González-Alvaro, Miguel Angel Descalzo, Loreto Carmona, et al.
Reumatologia Clinica|July 29, 2011
Pattern of use and safety of non-steroidal anti-inflammatory drugs in rheumatoid arthritis patients. A prospective analysis from clinical practiceIván Ferraz-Amaro, Sergio Machín, Loreto Carmona, et al.
The Journal of Rheumatology|January 6, 2004
Value of Disease Activity Score 28 (DAS28) and DAS28-3 compared to American College of Rheumatology-defined remission in rheumatoid arthritisAlejandro Balsa, Loreto Carmona, Isidoro González-Alvaro, et al.
Medicina Clinica|June 7, 2002
[Variations in the drug treatment of rheumatoid arthritis in Spain]Isidoro González-Alvaro, César Hernández-García, Virginia Villaverde García, et al.
Seminars in Arthritis and Rheumatism|November 6, 2007
Cancer in rheumatoid arthritis: occurrence, mortality, and associated factors in a South European populationLydia Abásolo, Enrique Júdez, Miguel Angel Descalzo, et al.
Trials|September 10, 2020
Subcutaneous Sarilumab in hospitalised patients with moderate-severe COVID-19 infection compared to the standard of care (SARCOVID): a structured summary of a study protocol for a randomised controlled trialRosario Garcia-Vicuña, Francisco Abad-Santos, Isidoro González-Alvaro, et al.
Diagnostics (Basel, Switzerland)|July 27, 2022
Anti-Citrullinated Protein Antibody Titers Are Independently Modulated by Both Disease Activity and Conventional or Biologic Anti-Rheumatic DrugsMiren Uriarte Ecenarro, Daniel Useros, Aranzazu Alfranca, et al.
The Journal of Rheumatology|May 18, 2010
Estimated cutoff points for the 28-joint disease activity score based on C-reactive protein in a longitudinal register of early arthritisIsabel Castrejón, Ana M Ortiz, Esther Toledano, et al.
Journal of Clinical Densitometry : the Official Journal of the International Society for Clinical Densitometry|June 19, 2007
Reproducibility of metacarpophalangeal bone mass measurements obtained by dual-energy X-ray absorptiometry in healthy volunteers and patients with early arthritisSantos Castañeda, Isidoro González-Alvaro, Francisco Rodríguez-Salvanés, et al.
Arthritis Research & Therapy|March 25, 2010
A rational use of glucocorticoids in patients with early arthritis has a minimal impact on bone massMonica Ibañez, Ana M Ortiz, Isabel Castrejón, et al.
Pageof 4